Navigation Links
VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
Date:8/1/2011

sponse to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy or FORTRESS; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the MAA; substantial competition; the impact on future sales based on specific indication and contraindications contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
2. VIVUS to Present at Three Upcoming Investor Conferences in March
3. VIVUS Provides Regulatory Update on QNEXA NDA
4. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. VIVUS to Present at Two Upcoming Investor Conferences
7. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
8. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
9. VIVUS Announces Sale of MUSE Assets to Meda
10. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
11. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  On August 5, 2015, the U.S. District Court ... denied motions to dismiss securities class action claims against ... of its directors. The class actions allege that the ... to artificially inflate Galena,s stock price, and during an ... inflated, sold massive amounts of their personally-held shares. ...
(Date:8/31/2015)... , Aug. 31, 2015  Dipexium Pharmaceuticals, Inc. ... on the development and commercialization of Locilex® (pexiganan cream ... announced plans to participate in four investor conferences in ... 2015 at the Sidoti & Company, LLC Emerging Growth ... . David P. Luci , President & Chief ...
(Date:8/31/2015)... MOUNTAIN VIEW, Calif. , Aug. 31, 2015 ... SAN) and the life sciences team at Google announced ... outcomes for people with type 1 and type 2 ... devices with Google,s expertise in analytics, miniaturized electronics and ... to improve diabetes care by developing new tools that ...
Breaking Medicine Technology:Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6
... PRINCETON, N.J., Sept. 24 DOR BioPharma, Inc. ... late-stage biotechnology company, announced today that it has entered into ... million. DOR,s North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated ... the terms of the agreements, DOR will sell approximately 15,200,000 ...
... Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced today ... the University of Texas Health Science Center ... 2 clinical trial using intravenous administration of REOLYSIN(R) in ... melanoma. The Principal Investigator is Dr. Devalingam Mahalingam, M.D., ...
Cached Medicine Technology:DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors 2DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors 3DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors 4Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial 2Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial 3Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial 4
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of Orthopedic Spine ... At OSSMC, Dr. Kovatis treats all surgical and non-surgical disorders of the leg, ankle ... entire musculoskeletal system, excluding the spine. , Dr. Paul Kovatis completed his orthopedic leg, ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare ... hold down costs? , In a commentary for The American Journal of ... concept of “clinical efficacy,” which would bind parties together in agreements to intervene ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... at the 16th Innovations in Healthcare(SM) Awards Event , on October 21, ... (ABL) Organization , recognizes innovative organizations and individuals who are dramatically reducing the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, ... ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, ... AdvantaClean’s National Call Center and website since Aug. 17. , The Greens have ...
(Date:8/31/2015)... ... August 31, 2015 , ... DR. LUCIANA ON ... (aka Dr. Luciana) received a total of three Silver Medal awards at ... Best (Dis)ability Film. Dr. Luciana co-wrote and co-produced this pilot with Del Weston, ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Actor/Writer/Director/Psychology Professor Luciana Lagana Receives Three Wins at the 2015 Global Independent Film Awards for the TV Pilot Dr. Luciana on Aging and Falling 2
... , TUESDAY, Sept. 27 (HealthDay News) -- Rude employee ... from many businesses, a new U.S. study finds. ... said they,d experienced or witnessed insensitive, disrespectful or rude ... consumers said this incivility makes them less likely to ...
... rates linked to climate change will increase in several European ... study, which will be presented today (27 September 2011) at ... Belgium, France, Spain and Portugal will see the biggest climate-induced ... The research is part of the Climate-TRAP project and ...
... birth can have on the lungs of babies could be ... prematurely but may be reversed in their teenage years, according ... at the European Respiratory Society Annual Congress in Amsterdam today ... allows enough time for the infant to fully grow and ...
... Reporter , MONDAY, Sept. 26 (HealthDay News) -- U.S. health ... of blood clots in women taking newer forms of birth ... short of a definitive statement, the U.S. Food and Drug ... higher risk of blood clots in women taking the "fourth ...
... an ongoing debate: Should men over a certain age be ... treatments that may result in significant side effects if they ... by researchers at UCLA,s Jonsson Comprehensive Cancer Center has shown ... while patients with a single comorbid condition such as peripheral ...
... News) -- People with heart disease who undergo cardiac rehabilitation ... rate after exercise, a new study suggests. Researchers at ... recovery live longer than those whose hearts remain revved up ... that can do that," study author Dr. Leslie Cho, director ...
Cached Medicine News:Health News:Climate change set to increase ozone-related deaths over next 60 years 2Health News:Lung function of moderately premature babies is reduced at 8-9 years but may improve with age 2Health News:Newer Contraceptive Pills Could Raise Clot Risk, FDA Warns 2Health News:Elderly patients may be undertreated for prostate cancer 2Health News:Elderly patients may be undertreated for prostate cancer 3Health News:Cardiac Rehab May Help Heart Patients Live Longer 2
... first time, the Integrated Cytometry Solution ... post-analytical solution coupled with complete LIS ... steps a sample undergoes - and ... one - it delivers a progressive ...
Convective Air Warming Blankets...
MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
Inquire...
Medicine Products: